Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analyst sentiment is moderately bullish: Fifteen brokerages give Janux Therapeutics an average “Moderate Buy” rating, including 10 buys and one strong buy, with an average 12-month price target of $36.46.
• Shares opened at $17.46, near the 50-day average of $17.60 and above the 200-day average of $15.34. The stock has traded between $12.12 and $35.34 over the past year, with a market capitalization of approximately $1.07 billion.
• Recent quarterly results fell short of expectations: Janux reported a loss of $0.35 per share versus the anticipated $0.25 loss and revenue of $10.27 million compared with estimates of $19.07 million. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen brokerages that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $36.46.

A number of equities research analysts have commented on the company. TD Cowen raised Janux Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Stifel Nicolaus set a $35.00 target price on Janux Therapeutics in a research report on Friday, August 7th. HC Wainwright reiterated a "buy" rating on shares of Janux Therapeutics in a research report on Monday, October 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Janux Therapeutics in a research note on Friday, October 16th. Finally, Guggenheim lowered their price target on Janux Therapeutics from $58.00 to $55.00 and set a "buy" rating on the stock in a report on Friday, August 7th.

Janux Therapeutics Price Performance

JANX opened at $17.46 on Tuesday. The company has a 50 day simple moving average of $17.60 and a two-hundred day simple moving average of $15.34. The firm has a market cap of $1.07 billion, a P/E ratio of -10.65 and a beta of 2.40. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.10). The firm had revenue of $10.27 million for the quarter, compared to analysts' expectations of $19.07 million. Equities analysts anticipate that Janux Therapeutics will post -1.70 earnings per share for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Janux Therapeutics in the second quarter worth $94,228,000. State Street Corp grew its stake in Janux Therapeutics by 22.0% during the second quarter. State Street Corp now owns 3,004,899 shares of the company's stock valued at $46,155,000 after acquiring an additional 540,882 shares in the last quarter. Alyeska Investment Group L.P. grew its stake in Janux Therapeutics by 2.9% during the second quarter. Alyeska Investment Group L.P. now owns 1,647,140 shares of the company's stock valued at $25,300,000 after acquiring an additional 46,051 shares in the last quarter. Algert Global LLC increased its holdings in Janux Therapeutics by 150.5% in the 2nd quarter. Algert Global LLC now owns 1,110,889 shares of the company's stock valued at $17,063,000 after acquiring an additional 667,492 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in Janux Therapeutics in the 2nd quarter valued at $13,985,000. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company's research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux's proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.